title: A case of lipoatrophy with insulin glargine: long-acting insulin analogs are not exempt from this complication.
authors.affiliation: Diabetes Reference Unit, Endocrinology Department, Clinic University Hospital Valencia, Avda. Blasco Ibáñez 17, 46010 Valencia, Spain. francisco.j.ampudia@uv.es
authors.forename: F Javier
authors.initials: FJ
authors.lastname: Ampudia-Blasco
authors.forename: Juan
authors.initials: J
authors.lastname: Girbes
authors.forename: Rafael
authors.initials: R
authors.lastname: Carmena
mesh_terms: D000328:Adult; D003923:Diabetes Mellitus, Lipoatrophic / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine